title: Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Cocito
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Silvia
authors.initials: S
authors.lastname: Mangiacavalli
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Bernasconi
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Anna A
authors.initials: AA
authors.lastname: Colombo
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Caldera
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Claudio S
authors.initials: CS
authors.lastname: Cartia
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Maya
authors.initials: M
authors.lastname: Ganzetti
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Troletti
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.affiliation: a Division of Hematology , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D019468:Disease Management; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D056747:Immunomodulation / Q000187:drug effects; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000069286:Bortezomib